Standardized SEC financial data for DEXCOM INC — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0001093557 · NASDAQ · Surgical & Medical Instruments & Apparatus.
Ratios for fiscal year 2025, standardized from SEC filings.
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.93B | $2.45B | $2.91B | $3.62B | $4.03B | $4.66B |
| Cost of revenue | $646.6M | $768.0M | $1.03B | $1.33B | $1.59B | $1.86B |
| Gross profit | $1.28B | $1.68B | $1.88B | $2.29B |
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $818.2M | $1.05B | $643.3M | $567.5M | $607.3M | $919.1M |
| Inventory | $234.7M | $357.3M | $306.7M | $559.6M | $542.6M | $629.1M |
| Total current assets | $3.42B | $3.68B | $3.67B | $4.43B |
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $475.6M | $442.5M | $669.5M | $748.5M | $989.5M | $1.44B |
| Capital expenditures | $199.0M | $389.2M | $364.8M | $236.6M | $358.8M | $363.5M |
| Free cash flow | $276.6M | $53.3M | $304.7M | $511.9M |
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/DXCM/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/DXCM/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"| $2.44B |
| $2.80B |
| R&D expense | $359.9M | $517.1M | $484.2M | $505.8M | $552.4M | $599.1M |
| SG&A expense | $618.2M | $810.5M | $1.01B | $1.19B | $1.29B | $1.29B |
| Operating income | $299.5M | $265.8M | $391.2M | $597.7M | $600.0M | $911.8M |
| EBITDA | $366.6M | $367.8M | $547.1M | $783.7M | $817.7M | $1.16B |
| Interest expense | $17.7M | $18.8M | $18.6M | $20.3M | $14.9M | $14.3M |
| Pretax income | $297.9M | $256.8M | $390.8M | $710.4M | $709.0M | $1.09B |
| Income tax | $251.8M | $39.9M | $49.6M | $168.9M | $132.8M | $252.1M |
| Net income | $549.7M | $216.9M | $341.2M | $541.5M | $576.2M | $836.3M |
| EPS (diluted) | $1.33 | $0.53 | $0.82 | $1.30 | $1.42 | $2.09 |
Standardized from DEXCOM INC's SEC filings — per-share figures split-adjusted. Full history via the API.
| $4.30B |
| $4.03B |
| Property, plant & equipment | $515.3M | $801.8M | — | — | — | — |
| Goodwill | $19.3M | $26.5M | $25.7M | $25.2M | $22.8M | $24.2M |
| Total assets | $4.29B | $4.93B | $5.39B | $6.26B | $6.48B | $6.34B |
| Total current liabilities | $614.1M | $720.8M | $1.84B | $1.56B | $2.93B | $2.14B |
| Total liabilities | $2.46B | $2.89B | $3.26B | $4.20B | $4.38B | $3.59B |
| Retained earnings | -$78.2M | $138.7M | $479.9M | $1.02B | $1.60B | $2.43B |
| Total equity | $1.83B | $2.04B | $2.13B | $2.07B | $2.10B | $2.75B |
| $630.7M |
| $1.08B |
| Investing cash flow | -$1.02B | -$216.1M | -$521.5M | -$507.2M | -$207.5M | $536.0M |
| Financing cash flow | $912.1M | $10.4M | -$552.5M | -$318.6M | -$734.8M | -$1.69B |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 |
| Share repurchases | $0 | $0 | $557.7M | $688.7M | $750.0M | $500.0M |